Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chi-Med's Lead Candidate Passes Phase III Colorectal Cancer Test

publication date: Mar 3, 2017
Hutchison China MediTech (Chi-Med) reported that its lead drug, fruquintinib, met its endpoints in a pivotal Phase III China trial. Fruquintinib was tested as a third-line treatment for metastatic colorectal cancer. Chi-Med, which has partnered the drug with Lilly , is now preparing to file for CFDA approval. The company said fruquintinib met both overall and progression-free survival in the heavily pre-treated patient population, though it is won't release specific results until the mid-2017 ASCO meeting. Fruquintinib, a VEGFR inhibitor, has an anti-angiogenic mechanism. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital